A citation-based method for searching scientific literature

S Sha, D Polidori, T Heise, J Natarajan, K Farrell, S-S Wang, D Sica, P Rothenberg, L Plum-Mörschel. Diabetes Obes Metab 2014
Times Cited: 137



Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
Times Cited: 2852




List of shared articles



Times cited

Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors.
Mohammad Shafi Kuchay, Khalid Jamal Farooqui, Sunil Kumar Mishra, Ambrish Mithal. Adv Exp Med Biol 2021
4


SGLT2 inhibitors, sodium and off-target effects: an overview.
Antonio De Pascalis, Giuseppe Cianciolo, Irene Capelli, Giuliano Brunori, Gaetano La Manna. J Nephrol 2021
1

Optimizing Management of Type 2 Diabetes and Its Complications in Patients With Heart Failure.
Christie A Schumacher, Elizabeth K Van Dril, Kayce M Shealy, Jennifer D Goldman. Clin Diabetes 2021
0

Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure.
Shruti S Joshi, Trisha Singh, David E Newby, Jagdeep Singh. Heart 2021
5

Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility.
Giulia Ferrannini, Gianluigi Savarese, Lars Rydén. Diabetes Res Clin Pract 2021
0

Effects of Canagliflozin on Hepatic Steatosis, Visceral Fat and Skeletal Muscle among Patients with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease.
Noriko Nishimiya, Kazuki Tajima, Kento Imajo, Akiko Kameda, Eiko Yoshida, Yu Togashi, Kazutaka Aoki, Tomio Inoue, Atsushi Nakajima, Daisuke Utsunomiya,[...]. Intern Med 2021
0

Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial.
Gian Pio Sorice, Francesca Cinti, Lucia Leccisotti, Domenico D'Amario, Margherita Lorusso, Maria Angela Guzzardi, Teresa Mezza, Camilla Cocchi, Umberto Capece, Pietro Manuel Ferraro,[...]. Diabetes Ther 2021
0

De-Intensification of Antidiabetic Treatment Using Canagliflozin in Patients with Heart Failure and Type 2 Diabetes: Cana-Switch-HF Study.
Luis M Pérez-Belmonte, Michele Ricci, Jaime Sanz-Cánovas, Lidia Cobos-Palacios, María D López-Carmona, M Isabel Ruiz-Moreno, Mercedes Millán-Gómez, M Rosa Bernal-López, Sergio Jansen-Chaparro, Ricardo Gómez-Huelgas. J Clin Med 2021
0


Sodium-glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: systematic review.
Roy Rasalam, John J Atherton, Gary Deed, Michael Molloy-Bland, Neale Cohen, Andrew Sindone. ESC Heart Fail 2021
0


The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure.
Petter Bjornstad, Peter J Greasley, David C Wheeler, Glenn M Chertow, Anna Maria Langkilde, Hiddo J L Heerspink, DaniëL H Van Raalte. J Card Fail 2021
0

Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes.
JingWei Li, Mark Woodward, Vlado Perkovic, Gemma A Figtree, Hiddo J L Heerspink, Kenneth W Mahaffey, Dick de Zeeuw, Frank Vercruysse, Wayne Shaw, David R Matthews,[...]. JACC Heart Fail 2020
30



Sodium-glucose co-transporter-2 inhibitors: peculiar "hybrid" diuretics that protect from target organ damage and cardiovascular events.
Riccardo Sarzani, Federico Giulietti, Chiara Di Pentima, Francesco Spannella. Nutr Metab Cardiovasc Dis 2020
3

Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.
James L Januzzi, Jialin Xu, JingWei Li, Wayne Shaw, Richard Oh, Michael Pfeifer, Javed Butler, Naveed Sattar, Kenneth W Mahaffey, Bruce Neal,[...]. J Am Coll Cardiol 2020
11